Skip to main content

Table 1 Patient, tumor and treatment characteristics

From: Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients

 

Total number of patients (%)

Gender

 Male

21 (75.0%)

 Female

7 (25.0%)

Median Age (range) in years

63 (48–91)

Median KPS (range) in %

80 (60–100%)

Primary Tumor Site

 NSCLC

13 (46.4%)

 SCLC

5 (17.9%)

 CRC

1 (3.6%)

 HCC

1 (3.6%)

 Breast cancer

1 (3.6%)

 Melanoma

1 (3.6%)

 RCC

2 (7.1%)

 Other

4 (14.3%)

Oligometastatic

21 (75%)

Oligoprogressive

7 (25%)

Total no of metastatic sites

 0

17 (60.7%)

 1

2 (7.1%)

 2

2 (7.1%)

 3

1 (3.6%)

  > 5

6 (21.4%)

Laterality

 Right

14 (50.0%)

 Left

14 (50.0%)

Metastasis status

 Synchronous

10 (35.7%)

 Metachronous

18 (64.3%)

Median time from primary diagnosis to adrenal gland metastasis (range) in months

14 (0–102)

Homogeneity distribution (%)

 Yes

26 (92.9%)

 No

2 (7.1%)

Forced dose restriction (%)

 Yes

14 (50.0%)

 No

14 (50.0%)

RT Technique

 3D conformal

4 (14.3%)

 Helical IMRT (Tomotherapy)

13 (46.4%)

 VMAT

11 (39.3%)

FFF photons utilized

 Yes

18 (64.3%)

 No

10 (35.7%)

Concurrent systemic therapy

 No

19 (67.9%)

 Yes

9 (32.1%)

  Chemotherapy

6 (66.7%)

  Targeted therapy

2 (22.2%)

  Immunotherapy

1 (11.1%)

 

Mean

Median (range)

Total dose (Gy)

47.3

50 (30–54)

Fractions (n)

9

10 (3–12)

Single dose (Gy)

5.6

5 (4–18)

BED10 (Gy)

73.5

75 (57.6–151.2)

Prescribed isodose line (%)

89

90 (80–90)

Median GTV volume (range) in cm3

27

42 (3–233)

Median PTV volume (range) in cm3

111

96 (16–346)

  1. KPS karnofsky performance score, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, CRC colorectal cancer, HCC hepatocellular cancer, RCC renal cell carcinoma, PTV planning target volume, BED10 biologically effective dose at α/β of 10, IMRT intensity-modulated radiotherapy, VMAT volumetric modulated arc therapy, FFF flattening filter free